Oct 4 (Reuters) - Johnson & Johnson ( JNJ ) said on

Friday it will discontinue a mid-stage field study evaluating

the efficacy of its antiviral drug candidate for the prevention

of dengue.

The decision to discontinue the study was part of a

reprioritization of the company's communicable diseases research

and development portfolio, J&J said.

In another mid-stage study, six of 10 participants on the

drug mosnodenvir showed no detectable dengue virus in their

blood after being exposed to the pathogen.